Sign in
Not yet recruitingNo phase

Artificial Intelligence-enabled Management of Atrial Fibrillation(ABLE-AF Trial)

Key facts

Who runs it
Korea University Anam Hospital
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
1,006 people, planned
Starts
1 Dec 2026
Expected to end
1 Jun 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • ECG Analysis Software AiTiALVDD
  • ECG Analysis Software AiTiALVSD
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Atrial fibrillation (AF) with rapid ventricular response confirmed on the day of screening or within 90 days before screening
  • Rapid ventricular response is defined as (i) a ventricular rate ≥110 bpm or (ii) a ventricular rate ≥100 bpm with related symptoms
  • AF can be confirmed by any guideline-accepted electrocardiographic (ECG) method, including 12-lead ECG, Holter ECG, or single-lead ECG (e.g., patch ECG or smartwatch)
  • AF must be documented for at least 10 seconds on a 12-lead ECG or at least 30 seconds on Holter or single-lead ECG

Who cannot take part

  • Acute decompensated heart failure requiring immediate hospitalization
  • Hospitalization for acute myocardial infarction (STEMI or NSTEMI) within the past 3 months
  • Diagnosis of severe valvular disease (e.g., severe aortic stenosis)
  • Left ventricular ejection fraction (LV EF) assessed by transthoracic echocardiography (TTE) within the past 6 months
  • Individuals aged 18 years or younger
  • If TTE was performed at another institution within the past 6 months, this exclusion criterion applies only when objective imaging data confirming LV EF are available
  • Hemodynamically unstable patients requiring immediate direct current cardioversion
  • Contraindication to AF pharmacotherapy (e.g., pregnancy)
  • 12-lead ECG not available in a format analyzable by the AI model

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Atrial fibrillation (AF) is the most common type of irregular heartbeat in adults. People with AF may also have other heart problems, including reduced heart pumping function or diseases affecting the heart muscle or heart valves. Identifying these problems early is important because the condition of the heart can affect treatment decisions and long-term care.

Read full original descriptionShow less

An ultrasound examination of the heart, called transthoracic echocardiography (TTE) or an echocardiogram, is commonly used to check how well the heart pumps blood and to look for structural problems, such as heart valve disease. However, an echocardiogram requires special equipment and trained healthcare professionals to perform and interpret the examination. Because of these requirements, it may not always be available when needed. This can be particularly challenging in situations where heart function needs to be evaluated quickly, such as when a patient with AF has a very fast heart rate. Delays may also occur in outpatient settings because of limited availability of echocardiography.

Artificial intelligence (AI) technology may provide an additional way to identify patients who are more likely to have heart problems and who may benefit from further evaluation. A standard 12-lead electrocardiogram (ECG) is a simple and widely available test that records the electrical activity of the heart. AI-based computer programs can analyze information contained in an ECG that may not be easily recognized through routine interpretation.

This study will use two AI-based ECG programs, called AiTiALVSD and AiTiALVDD. AiTiALVSD analyzes a standard 12-lead ECG to identify patients who may have reduced heart pumping function. Previous studies have evaluated this program in different clinical settings, including patients with AF and a fast heart rate.

AiTiALVDD analyzes the ECG for signs that may be associated with difficulty in the heart relaxing and filling with blood. Problems with heart relaxation and filling may occur in several types of heart disease, including heart valve disease, abnormal thickening of the heart muscle, heart disease related to high blood pressure, diseases affecting the heart muscle, and coronary artery disease. Importantly, some patients may have these conditions even when the heart's overall pumping function is normal. Therefore, evaluating only pumping function may not identify all patients who have important underlying heart disease.

By using AiTiALVSD and AiTiALVDD together, this study aims to evaluate a broader AI-based approach to identifying heart problems in patients with AF. AiTiALVSD may help identify patients who are more likely to have reduced heart pumping function, while AiTiALVDD may provide additional information about possible problems with heart relaxation and filling. A high-risk result from AiTiALVDD may serve as a signal that further heart evaluation should be considered, including evaluation for significant heart valve disease or other underlying structural heart conditions.

The purpose of this study is to evaluate whether using these two AI-based ECG programs together can help identify patients with AF who may have previously unrecognized problems with heart function or underlying heart disease. Patients identified by the AI analysis as being at higher risk may receive further evaluation as appropriate to determine whether additional heart disease is present.

The study will also evaluate the clinical usefulness of this AI-based ECG approach in routine care. The goal is not to replace an echocardiogram or a physician's clinical assessment. Instead, AI-based ECG analysis may serve as an additional screening tool to help healthcare professionals identify patients who may benefit from further cardiac testing.

By using information from a routinely performed ECG, this approach may help support earlier and more efficient evaluation of heart function and underlying heart disease in patients with AF. The results of this study will help determine whether combining AiTiALVSD and AiTiALVDD can provide useful information for deciding which patients may need additional cardiac evaluation and whether this approach can improve the process of identifying clinically important heart conditions.

The 2 groups in the trial

  • Conventional TreatmentExisting treatment, for comparison

    Pharmacologic treatment will be initiated after TTE is performed, in accordance with guideline recommendations. * Rate control: In accordance with guideline recommendations, the choice of rate-control agent may be based on LV EF (≤40% or not). However, in patients requiring acute rate control, agents that can be used regardless of LV EF (beta-blocker, digoxin) may be used without prior TTE.1 * Rhythm control: In accordance with guideline recommendations, antiarrhythmic drug therapy may be initiated after assessment of LV EF and structural heart disease. Because oral amiodarone is not recommended as first-line therapy when LV EF \>40%, it may not be used preferentially without information on LV EF. 1,2 * When underlying heart failure is suspected, guideline-recommended pharmacotherapy will also be administered; however, when acute or congestive heart failure is suspected, agents that can be used without LV EF information (e.g., diuretics) may be initiated.

    Treatment: ECG Analysis Software AiTiALVSD

  • AI-Guided TreatmentTreatment being tested

    Guideline-directed AF pharmacotherapy may be initiated based on the AI-predicted LV EF obtained on the day of enrollment. Because patients with AF undergo a 12-lead ECG for clinical purposes, in the investigational group the AI-predicted LV EF becomes available immediately once the AI-enabled 12-lead ECG is performed. * TTE may also be performed in the investigational group, in accordance with guideline recommendations, to assess structural heart disease and left atrial substrate, and treatment may be modified based on the TTE results. * Rate control: The choice of agent may be based on the AI-predicted LV EF.1 * Rhythm control: If the AI-predicted LV EF is \>40%, there is no history of coronary artery disease, and there is no suspicion of moderate-to-severe valvular disease (e.g., no murmur), a Class IC antiarrhythmic drug (propafenone, flecainide, etc.) may be used in accordance with guideline recommendations. If the AI-predicted LV EF is ≤40%, oral amiodarone may be administered.1,2

    Treatment: ECG Analysis Software AiTiALVDD

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Artificial Intelligence-enabled Management of Atrial Fibrillation: a Randomized Clinical Trial (ABLE-AF Trial)
Record updated
17 November 2026